Case 083Credit and leveraged financeWarm up
A food company has Rs 700 crore of debt, Rs 50 crore of cash and a 3.5x net leverage covenant. EBITDA falls from Rs 200 crore to Rs 170 crore. Is the covenant breached, how much headroom was there, and how large an equity cure fixes it?
1The situation
Nayaka Foods, a packaged snacks maker owned by a private equity fund, has Rs 700 crore of term debt and Rs 50 crore of cash. Its loan agreement says net debt must not exceed 3.5x EBITDA over the last twelve months, tested every quarter.
Last year's EBITDA was Rs 200 crore. A spike in edible oil and packaging costs has pushed the latest twelve-month figure down to Rs 170 crore. The agreement lets the sponsor inject equity to cure a breach. The fund's partner asks you where Nayaka stands.
2Your task
Compute leverage before and after, the headroom Nayaka had, and the size of the equity cure, and explain why the answer depends on how the agreement counts the cure.
Quick check
How far could EBITDA have fallen from Rs 200 crore before breaching 3.5x?
Worked solution
Try it on paper, then open one step at a time.
30-second answerThe answer to give first
Yes: net leverage rises from 3.25x to 3.82x, through the 3.5x line. Net debt is 700 less 50, Rs 650 crore. Nayaka could only lose Rs 14.3 crore of EBITDA, about 7%, before breaching. A cure that cuts net debt must be Rs 55 crore; if the agreement counts the cure as EBITDA, Rs 15.7 crore is enough.
Step 1How much headroom did Nayaka really have?
Measure headroom in EBITDA, not in turns of leverage. At 3.25x against a 3.5x limit the gap looks like a quarter turn, but it means EBITDA can fall only to Rs 185.7 crore, a 7.1% drop. A household that spends 90% of its income has 10% headroom on paper, but one month of lost overtime wipes it out. Seen from the debt side, Nayaka could have borrowed Rs 50 crore more at Rs 200 crore of EBITDA. Either way, a cost spike of the kind food companies see every few years uses it all.
Step 2How big must the equity cure be?
It depends on what the equity cureA right in a loan agreement letting the owners put in new equity after a covenant breach, which is then counted as if it had improved the ratio. is allowed to touch. If the cash goes to cut net debt, it must take net debt down to 3.5 times 170, Rs 595 crore, so the cure is Rs 55 crore. If the agreement treats the cure as added EBITDA, the sponsor only needs to lift EBITDA to Rs 185.7 crore, a cure of Rs 15.7 crore. That is the same breach fixed with about a third of the money, which is why sponsors negotiate for EBITDA cures and lenders resist them.
| Rs crore | Before | After | Cure to net debt | Cure as EBITDA |
|---|---|---|---|---|
| Net debt | 650 | 650 | 595 | 650 |
| EBITDA, last twelve months | 200 | 170 | 170 | 185.7 |
| Net debt / EBITDA | 3.25x | 3.82x | 3.50x | 3.50x |
| Equity needed | 55 | 15.7 |
Step 3What would you tell the sponsor beyond the cure amount?
A cure buys one test date, not a fixed business. If costs stay high, EBITDA of Rs 170 crore is the new normal and the next quarter fails again. Agreements usually limit how often a cure can be used and whether it can be used in consecutive quarters; read the clause before promising the partner anything, because the exact limits differ by agreement. The alternatives are asking lenders for a covenant reset in exchange for a fee and a higher margin, or prepaying debt from a disposal. A fund that cures once and then resets on better terms has used the cure well.
Close with the limit of the arithmetic. EBITDA in a covenant is defined by the agreement, often with add-backs for one-off costs, so the reported Rs 170 crore may not be the covenant figure. If the agreement lets Nayaka add back, say, a one-off plant shutdown cost, the breach could shrink or vanish. The first question a leveraged finance banker asks is which EBITDA the covenant uses.
Where candidates lose it
Candidates often use gross debt of Rs 700 crore, get 3.5x before the fall and 4.1x after, and conclude Nayaka was already at the limit. The covenant says net, so cash comes off first.
The second miss is giving one cure number without asking how the agreement counts it. The difference between Rs 55 crore and about Rs 16 crore is the whole negotiation.
What the interviewer asks next
- What if the Rs 50 crore of cash includes Rs 20 crore trapped in a subsidiary that cannot pay dividends?
- Why do lenders often refuse to let a cure reduce the debt used for pricing step-downs?
- EBITDA keeps falling to Rs 160 crore next quarter. What are the sponsor's options now?
Company names and figures are illustrative.
